Reviving B-Factors: Retrospective Normalized B-Factor Analysis of c-ros Oncogene 1 Receptor Tyrosine Kinase and Anaplastic Lymphoma Kinase L1196M with Crizotinib and Lorlatinib

door Johnson, Ted W., Gallego, Rebecca A., Brooun, Alexei, Gehlhaar, Dan, McTigue, Michele
Gepubliceerd in ACS Med Chem Lett (2018)

Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors

door McTigue, Michele, Murray, Brion William, Chen, Jeffrey H., Deng, Ya-Li, Solowiej, James, Kania, Robert S.
Gepubliceerd in 2012

Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors

door Qi, Jie, McTigue, Michele A., Rogers, Andrew, Lifshits, Eugene, Christensen, James G., Jänne, Pasi A., Engelman, Jeffrey A.
Gepubliceerd in 2011

Reviving B-Factors: Activating ALK Mutations Increase Protein Dynamics of the Unphosphorylated Kinase

door Johnson, Ted W., Bolanos, Ben, Brooun, Alexei, Gallego, Rebecca A., Gehlhaar, Dan, Jalaie, Mehran, McTigue, Michele, Timofeevski, Sergei
Gepubliceerd in ACS Med Chem Lett (2018)

Multiple conformational states of the HPK1 kinase domain in complex with sunitinib reveal the structural changes accompanying HPK1 trans-regulation

door Johnson, Eric, McTigue, Michele, Gallego, Rebecca A., Johnson, Ted W., Timofeevski, Sergei, Maestre, Michael, Fisher, Timothy S., Kania, Robert, Sawasdikosol, Sansana, Burakoff, Steven, Cronin, Ciarán N.
Gepubliceerd in J Biol Chem (2019)

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

door Gajiwala, Ketan S., Wu, Joe C., Christensen, James, Deshmukh, Gayatri D., Diehl, Wade, DiNitto, Jonathan P., English, Jessie M., Greig, Michael J., He, You-Ai, Jacques, Suzanne L., Lunney, Elizabeth A., McTigue, Michele, Molina, David, Quenzer, Terri, Wells, Peter A., Yu, Xiu, Zhang, Yan, Zou, Aihua, Emmett, Mark R., Marshall, Alan G., Zhang, Hui-Min, Demetri, George D.
Gepubliceerd in 2009

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

door Awad, Mark M., Katayama, Ryohei, McTigue, Michele, Liu, Wei, Deng, Ya-Li, Brooun, Alexei, Friboulet, Luc, Huang, Donghui, Falk, Matthew D., Timofeevski, Sergei, Wilner, Keith D., Lockerman, Elizabeth L., Khan, Tahsin M., Mahmood, Sidra, Gainor, Justin F., Digumarthy, Subba R., Stone, James R., Mino-Kenudson, Mari, Christensen, James G., Iafrate, A. John, Engelman, Jeffrey A., Shaw, Alice T.
Gepubliceerd in 2013

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

door Zou, Helen Y., Li, Qiuhua, Engstrom, Lars D., West, Melissa, Appleman, Vicky, Wong, Katy A., McTigue, Michele, Deng, Ya-Li, Liu, Wei, Brooun, Alexei, Timofeevski, Sergei, McDonnell, Scott R. P., Jiang, Ping, Falk, Matthew D., Lappin, Patrick B., Affolter, Timothy, Nichols, Tim, Hu, Wenyue, Lam, Justine, Johnson, Ted W., Smeal, Tod, Charest, Al, Fantin, Valeria R.
Gepubliceerd in Proc Natl Acad Sci U S A (2015)

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

door Shaw, Alice T., Friboulet, Luc, Leshchiner, Ignaty, Gainor, Justin F., Bergqvist, Simon, Brooun, Alexei, Burke, Benjamin J., Deng, Ya-Li, Liu, Wei, Dardaei, Leila, Frias, Rosa L., Schultz, Kate R., Logan, Jennifer, James, Leonard P., Smeal, Tod, Timofeevski, Sergei, Katayama, Ryohei, Iafrate, A. John, Le, Long, McTigue, Michele, Getz, Gad, Johnson, Ted W., Engelman, Jeffrey A.
Gepubliceerd in N Engl J Med (2015)